デフォルト表紙
市場調査レポート
商品コード
1467804

不妊治療薬市場レポート:薬剤クラス別、投与経路別、流通チャネル別、エンドユーザー別、地域別、2024~2032年

Infertility Drugs Market Report by Drug Class (Gonadotropin, Aromatase Inhibitors, Selective Estrogen Receptor Modulators, Biguanides, and Others), Route of Administration, Distribution Channel, End User, and Region 2024-2032

出版日: | 発行: IMARC | ページ情報: 英文 135 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.74円
不妊治療薬市場レポート:薬剤クラス別、投与経路別、流通チャネル別、エンドユーザー別、地域別、2024~2032年
出版日: 2024年04月08日
発行: IMARC
ページ情報: 英文 135 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の不妊治療薬市場規模は2023年に39億米ドルに達しました。今後、IMARC Groupは、2024~2032年にかけて4.7%の成長率(CAGR)を示し、2032年までに60億米ドルに達すると予測しています。

不妊治療薬とは、不妊症を治療し、個人の生殖機能を高めるために使用される様々な薬剤を指します。不妊治療薬は、注射または経口投与されます。一般的に使用される不妊治療薬には、ゴナドトロフィン、アロマターゼ阻害薬、選択的エストロゲン受容体モジュレーター(SERM)、ビグアナイド系薬剤、排卵刺激薬、ドーパミン作動薬、三環系抗うつ薬などがあります。これらの薬剤は、女性では卵巣の排卵と卵胞発育を刺激することによって作用し、男性ではテストステロンレベルを回復させ、精子の質を向上させることによって妊娠をもたらします。近年、不妊治療薬は妊娠できないカップルの間で人気を集めています。

不妊治療薬の市場動向:

不妊治療薬は、妊娠に寄与する個人の能力を回復させることで、カップルの妊娠の可能性を高める手助けをします。その結果、不妊症や流産が増加し、市場の成長を促す主要要因となっています。これに加えて、利用可能な治療オプションに関する認識を広めるために各国政府が行ったいくつかの好意的な取り組みが、不妊治療薬の需要を刺激しています。さらに、多忙な勤務スケジュールやそれに伴うストレス、ライフスタイルの変化により、がん、肥満、糖尿病、甲状腺、多嚢胞性卵巣症候群(PCOS)、更年期障害などの慢性疾患の有病率が大幅に増加しています。これに加え、妊娠の遅れ、晩婚化、アルコールや薬剤の過剰摂取、喫煙などの不健康な習慣による出生率の低下が、製品の採用率を加速させています。さらに、複数の主要企業が研究開発(R&D)活動に取り組んでおり、有効性が強化され、必要量が少なく、副作用の少ない革新的な不妊治療薬を発売しています。さらに、これらの薬剤を開発するための公的資金の増加や、様々な規制機関からの迅速な薬剤承認が、市場の成長を後押ししています。ジェネリック医薬品への需要の高まり、医療インフラの改善、消費支出能力の上昇、急速な都市化、技術の進歩など、その他の要因も市場成長を後押ししています。

本レポートで扱う主要質問

  • 世界の不妊治療薬市場はこれまでどのように推移し、今後どのように推移するのか?
  • COVID-19が世界の不妊治療薬市場に与えた影響は?
  • 主要地域市場は?
  • 薬剤クラス別の市場内訳は?
  • 投与経路別の市場内訳は?
  • 販売チャネル別の市場内訳は?
  • エンドユーザー別の市場内訳は?
  • 業界のバリューチェーンにおける様々な段階とは?
  • 業界の主要な促進要因と課題は何か?
  • 世界の不妊治療薬市場の構造と主要参入企業は?
  • 業界の競合の程度は?

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 調査手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要産業動向

第5章 不妊治療薬の世界市場

  • 市場概要
  • 市場実績
  • COVID-19の影響
  • 市場予測

第6章 市場内訳:薬剤クラス別

  • ゴナドトロピン
  • アロマターゼ阻害薬
  • 選択的エストロゲン受容体モジュレーター(SERMs)
  • ビグアナイド薬
  • その他

第7章 市場内訳:投与経路別

  • 経口剤
  • 静脈内投与
  • 皮下注射
  • 筋肉内

第8章 市場内訳:流通チャネル別

  • 病院薬局
  • 小売薬局
  • その他

第9章 市場内訳:エンドユーザー別

  • 男性
  • 女性

第10章 市場内訳:地域別

  • 北米
    • 米国
    • カナダ
  • アジア太平洋
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア
    • インドネシア
    • その他
  • 欧州
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン
    • ロシア
    • その他
  • ラテンアメリカ
    • ブラジル
    • メキシコ
    • その他
  • 中東・アフリカ
    • 市場動向
    • 市場内訳:国別
    • 市場予測

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会
  • 脅威

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の程度
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Abbott Laboratories
    • Bayer AG
    • Ferring Pharmaceuticals
    • Livzon Pharmaceutical Group Inc.
    • Mankind Pharma
    • Merck & Co. Inc.
    • Merck KGaA
    • Novartis AG
    • Pfizer Inc.
    • Sanofi S.A.
    • Theramex
図表

List of Figures

  • Figure 1: Global: Infertility Drugs Market: Major Drivers and Challenges
  • Figure 2: Global: Infertility Drugs Market: Sales Value (in Billion US$), 2018-2023
  • Figure 3: Global: Infertility Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
  • Figure 4: Global: Infertility Drugs Market: Breakup by Drug Class (in %), 2023
  • Figure 5: Global: Infertility Drugs Market: Breakup by Route of Administration (in %), 2023
  • Figure 6: Global: Infertility Drugs Market: Breakup by Distribution Channel (in %), 2023
  • Figure 7: Global: Infertility Drugs Market: Breakup by End User (in %), 2023
  • Figure 8: Global: Infertility Drugs Market: Breakup by Region (in %), 2023
  • Figure 9: Global: Infertility Drugs (Gonadotropin) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 10: Global: Infertility Drugs (Gonadotropin) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 11: Global: Infertility Drugs (Aromatase Inhibitors) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 12: Global: Infertility Drugs (Aromatase Inhibitors) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 13: Global: Infertility Drugs (Selective Estrogen Receptor Modulators (SERMs)) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 14: Global: Infertility Drugs (Selective Estrogen Receptor Modulators (SERMs)) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 15: Global: Infertility Drugs (Biguanides) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 16: Global: Infertility Drugs (Biguanides) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 17: Global: Infertility Drugs (Other Drug Classes) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 18: Global: Infertility Drugs (Other Drug Classes) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 19: Global: Infertility Drugs (Oral) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 20: Global: Infertility Drugs (Oral) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 21: Global: Infertility Drugs (Intravenous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 22: Global: Infertility Drugs (Intravenous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 23: Global: Infertility Drugs (Subcutaneous) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 24: Global: Infertility Drugs (Subcutaneous) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 25: Global: Infertility Drugs (Intramuscular) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 26: Global: Infertility Drugs (Intramuscular) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 27: Global: Infertility Drugs (Hospital Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 28: Global: Infertility Drugs (Hospital Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 29: Global: Infertility Drugs (Retail Pharmacies) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 30: Global: Infertility Drugs (Retail Pharmacies) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 31: Global: Infertility Drugs (Other Distribution Channels) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 32: Global: Infertility Drugs (Other Distribution Channels) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 33: Global: Infertility Drugs (Male) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 34: Global: Infertility Drugs (Male) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 35: Global: Infertility Drugs (Female) Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 36: Global: Infertility Drugs (Female) Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 37: North America: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 38: North America: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 39: United States: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 40: United States: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 41: Canada: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 42: Canada: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 43: Asia-Pacific: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 44: Asia-Pacific: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 45: China: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 46: China: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 47: Japan: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 48: Japan: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 49: India: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 50: India: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 51: South Korea: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 52: South Korea: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 53: Australia: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 54: Australia: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 55: Indonesia: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 56: Indonesia: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 57: Others: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 58: Others: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 59: Europe: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 60: Europe: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 61: Germany: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 62: Germany: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 63: France: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 64: France: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 65: United Kingdom: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 66: United Kingdom: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 67: Italy: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 68: Italy: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 69: Spain: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 70: Spain: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 71: Russia: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 72: Russia: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 73: Others: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 74: Others: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 75: Latin America: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 76: Latin America: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 77: Brazil: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 78: Brazil: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 79: Mexico: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 80: Mexico: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 81: Others: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 82: Others: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 83: Middle East and Africa: Infertility Drugs Market: Sales Value (in Million US$), 2018 & 2023
  • Figure 84: Middle East and Africa: Infertility Drugs Market: Breakup by Country (in %), 2023
  • Figure 85: Middle East and Africa: Infertility Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
  • Figure 86: Global: Infertility Drugs Industry: SWOT Analysis
  • Figure 87: Global: Infertility Drugs Industry: Value Chain Analysis
  • Figure 88: Global: Infertility Drugs Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Infertility Drugs Market: Key Industry Highlights, 2023 and 2032
  • Table 2: Global: Infertility Drugs Market Forecast: Breakup by Drug Class (in Million US$), 2024-2032
  • Table 3: Global: Infertility Drugs Market Forecast: Breakup by Route of Administration (in Million US$), 2024-2032
  • Table 4: Global: Infertility Drugs Market Forecast: Breakup by Distribution Channel (in Million US$), 2024-2032
  • Table 5: Global: Infertility Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
  • Table 6: Global: Infertility Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
  • Table 7: Global: Infertility Drugs Market: Competitive Structure
  • Table 8: Global: Infertility Drugs Market: Key Players
目次
Product Code: SR112024A5239

The global infertility drugs market size reached US$ 3.9 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 6.0 Billion by 2032, exhibiting a growth rate (CAGR) of 4.7% during 2024-2032.

Infertility drugs refer to various medications used to treat infertility and enhance the reproductive health of an individual. They are either injected or taken orally. Some commonly used infertility drugs include gonadotrophins, aromatase inhibitors, selective estrogen receptor modulators (SERMs), biguanides, ovulatory stimulants, dopamine agonists, and tricyclic antidepressants. They work by stimulating ovulation and follicle development of the ovary in women, whereas they help restore testosterone levels and improve the quality of sperm in men to bring about pregnancy. In recent years, infertility drugs have gained traction among couples who are unable to conceive.

Infertility Drugs Market Trends:

Infertility drugs assist in enhancing the chances of pregnancy in couples by restoring the ability of an individual to contribute to conception. As a result, the rising incidences of infertility and miscarriage represents the primary factor driving the market growth. Besides this, several favorable initiatives undertaken by governments of various countries to spread awareness regarding the available treatment options are catalyzing the demand for infertility drugs. Additionally, there has been a significant increase in the prevalence of chronic diseases, such as cancer, obesity, diabetes, thyroid, polycystic ovarian syndrome (PCOS), and menopausal disorders, on account of hectic work schedules, accompanying stress, and lifestyle changes. Along with this, the declining fertility rates due to delayed pregnancies, late marriages, and unhealthy habits, such as excessive consumption of alcohol, drugs, and smoking, are accelerating the product adoption rates. Furthermore, several key players are engaging in research and development (R&D) activities to launch innovative infertility drugs with enhanced efficacy, lower dosage requirements, and fewer side effects. Moreover, the increasing public funding for developing these drugs and faster drug approvals from various regulatory bodies are propelling the market growth. Other factors, including the escalating demand for generic medicines, improving healthcare infrastructure, rising consumer expenditure capacities, rapid urbanization, and technological advancements, are also providing a positive thrust to the market growth.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global infertility drugs market report, along with forecasts at the global, regional and country level from 2024-2032. Our report has categorized the market based on drug class, route of administration, distribution channel and end user.

Breakup by Drug Class:

Gonadotropin

Aromatase Inhibitors

Selective Estrogen Receptor Modulators (SERMs)

Biguanides

Others

Breakup by Route of Administration:

Oral

Intravenous

Subcutaneous

Intramuscular

Breakup by Distribution Channel:

Hospital Pharmacies

Retail Pharmacies

Others

Breakup by End User:

Male

Female

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Abbott Laboratories, Bayer AG, Ferring Pharmaceuticals, Livzon Pharmaceutical Group Inc., Mankind Pharma, Merck & Co. Inc., Merck KGaA, Novartis AG, Pfizer Inc., Sanofi S.A. and Theramex.

Key Questions Answered in This Report:

  • How has the global infertility drugs market performed so far and how will it perform in the coming years?
  • What has been the impact of COVID-19 on the global infertility drugs market?
  • What are the key regional markets?
  • What is the breakup of the market based on the drug class?
  • What is the breakup of the market based on the route of administration?
  • What is the breakup of the market based on the distribution channel?
  • What is the breakup of the market based on the end user?
  • What are the various stages in the value chain of the industry?
  • What are the key driving factors and challenges in the industry?
  • What is the structure of the global infertility drugs market and who are the key players?
  • What is the degree of competition in the industry?

Table of Contents

1 Preface

2 Scope and Methodology

  • 2.1 Objectives of the Study
  • 2.2 Stakeholders
  • 2.3 Data Sources
    • 2.3.1 Primary Sources
    • 2.3.2 Secondary Sources
  • 2.4 Market Estimation
    • 2.4.1 Bottom-Up Approach
    • 2.4.2 Top-Down Approach
  • 2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

  • 4.1 Overview
  • 4.2 Key Industry Trends

5 Global Infertility Drugs Market

  • 5.1 Market Overview
  • 5.2 Market Performance
  • 5.3 Impact of COVID-19
  • 5.4 Market Forecast

6 Market Breakup by Drug Class

  • 6.1 Gonadotropin
    • 6.1.1 Market Trends
    • 6.1.2 Market Forecast
  • 6.2 Aromatase Inhibitors
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3 Selective Estrogen Receptor Modulators (SERMs)
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast
  • 6.4 Biguanides
    • 6.4.1 Market Trends
    • 6.4.2 Market Forecast
  • 6.5 Others
    • 6.5.1 Market Trends
    • 6.5.2 Market Forecast

7 Market Breakup by Route of Administration

  • 7.1 Oral
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2 Intravenous
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3 Subcutaneous
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4 Intramuscular
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast

8 Market Breakup by Distribution Channel

  • 8.1 Hospital Pharmacies
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2 Retail Pharmacies
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3 Others
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast

9 Market Breakup by End User

  • 9.1 Male
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2 Female
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast

10 Market Breakup by Region

  • 10.1 North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2 Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3 Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4 Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5 Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11 SWOT Analysis

  • 11.1 Overview
  • 11.2 Strengths
  • 11.3 Weaknesses
  • 11.4 Opportunities
  • 11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

  • 13.1 Overview
  • 13.2 Bargaining Power of Buyers
  • 13.3 Bargaining Power of Suppliers
  • 13.4 Degree of Competition
  • 13.5 Threat of New Entrants
  • 13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

  • 15.1 Market Structure
  • 15.2 Key Players
  • 15.3 Profiles of Key Players
    • 15.3.1 Abbott Laboratories
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
    • 15.3.2 Bayer AG
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
    • 15.3.3 Ferring Pharmaceuticals
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
    • 15.3.4 Livzon Pharmaceutical Group Inc.
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
    • 15.3.5 Mankind Pharma
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
    • 15.3.6 Merck & Co. Inc.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
    • 15.3.7 Merck KGaA
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
    • 15.3.8 Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
    • 15.3.9 Pfizer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
    • 15.3.10 Sanofi S.A.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11 Theramex
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio